Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report

Complementary Therapies in Medicine

Volumn 27, Issue , 2016, Pages 108-113

  Demiray, M ^a   Sahinbas, H ^b   Atahan, S ^c   Demiray, H ^a   Selcuk, D ^a   Yildirim, I ^d   Atayoglu, A T ^e  

^a Medicana International Istanbul   (Turkey)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Patonet Pathology Laboratory   (Turkey)

^d Ali Osman Sonmez Oncology Hospital   (Turkey)

^e ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

Author keywords

Adenoid cystic carcinoma; Arantal; Curcumin; Imatinib; Integrative medicine

Indexed keywords

CISPLATIN; CURCUMIN; DIPHENHYDRAMINE; ETOPOSIDE; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RANITIDINE; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; STEM CELL FACTOR RECEPTOR;

ADENOID CYSTIC CARCINOMA; ADJUVANT RADIOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CASE REPORT; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; LUNG METASTASIS; MALE; SALIVARY GLAND CARCINOMA; TUMOR BIOPSY; CARCINOMA, ADENOID CYSTIC; COMBINATION DRUG THERAPY; METABOLISM; MIDDLE AGED; PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; CURCUMIN; DRUG THERAPY, COMBINATION; HUMANS; IMATINIB MESYLATE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84978306024     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2016.06.009     Document Type: Article

References (31)

1. 1 Persson, M., Andrén, Y., Mark, J., Horlings, H.M., Persson, F., Stenman, G., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106 (2009), 18740–18744.
2. 2 Prognostic Factors in Head and Neck Adenoid Cystic Carcinoma. Oral Oncol 42 (2006), 139–146.
3. 3 Chummun, S., McLean, N.R., Kelly, C.G., et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg 54 (2001), 476–480.
4. 4 Dodd, R.L., Slevin, N.J., Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 42 (2006), 759–769.
5. 5 Dillon, P.M., Chakraborty, S., Moskaluk, C.A., Joshi, P.J., Thomas, C.Y., Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. Head Neck, 2014, 10.1002/hed.23925.
6. 6 Bjørndal, K., Krogdahl, A., Therkildsen, M.H., et al. Salivary gland carcinoma in Denmark 1990–2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 47 (2011), 677–682.
7. 7 Vander Poorten, V.L., Balm, A.J., Hilgers, F.J., et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 85 (1999), 2255–2264.
8. 8 Stell, P.M., Adenoid cystic carcinoma. Clin Otolaryngol Allied Sci 11 (1986), 267–291.
9. 9 Laurie, S.A., Ho, A.L., Fury, M.G., Sherman, E., Pfister, D.G., Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 12 (2011), 815–824.
10. 10 Jeng, Y.M., Lin, C.Y., Hsu, H.C., Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154 (2000), 107–111.
11. 11 Joensuu, H., Dimitrijevic, S., Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33 (2001), 451–455.
12. 12 Phuchareon, Janyaporn, van Zante, Annemieke, Overdevest, Jonathan B., McCormick, Frank, Eisele, David W., Tetsu, Osamu, C-Kit expression is rate-Limiting for stem cell factor-Mediated disease progression in adenoid cystic carcinoma of the salivary glands. Transl Oncol, 7(October (5)), 2014, 545, 10.1016/j.tranon.2014.07.006 Published online 24.10.14.
13. 13 Goel, A., Kunnumakkara, A.B., Aggarwal, B.B., Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 75 (2008), 787–809.
14. 14 Goel, A., Aggarwal, B.B., Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62 (2010), 919–930.
15. 15 Anand, P., Sundaram, C., Jhurani, S., Kunnumakkara, A.B., Aggarwal, B.B., Curcumin and cancer: an old-age disease with an age-old solution. Cancer Lett 267 (2008), 133–164.
16. 16 Guo, Y., Li, Y., Shan, Q., He, G., Lin, J., Gong, Y., Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell Biol 65 (2015), 1–11.
17. 17 Wu, L.X., Wu, Y., Chen, R.J., et al. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. Acta Pharmacol Sin 35 (2014), 401–409.
18. 18 Sun, Z.J., Chen, G., Zhang, W., et al. Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma. Mol Pharmacol 79 (2011), 106–118.
19. 19 Henrotin, Y., Priem, F., Mobasheri, A., Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. SpringerPlus, 2, 2013, 56.
20. 20 Young, H., Baum, R., Cremerius, U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review andEORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35 (1999), 1773–1782.
21. 21 O'Brien, S.G., Guilhot, F., Larson, R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003), 994–1004.
22. 22 Demetri, G.D., von Mehren, M., Blanke, C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002), 472–480.
23. 23 Heinrich, M.C., Corless, C.L., Demetri, G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003), 4342–4349.
24. 24 Vila, L., Liu, H., Al-Quran, S.Z., Coco, D.P., Dong, H.J., Liu, C., Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 22 (2009), 1296–1302.
25. 25 Sun, Z.J., Chen, G., Hu, X., et al. Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 15 (2010), 850–863.
26. 26 Guo, Y., Li, Y., Shan, Q., He, G., Lin, J., Gong, Y., Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. Int J Biochem Cell Biol 65 (2015), 1–11.
27. 27 Zhang, J., Peng, B., NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. Cell Prolif 42 (2009), 150–161.
28. 28 Kunnumakkara, A.B., Diagaradjane, P., Anand, P., et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 125 (2009), 2187–2197.
29. 29 Singh, S., Aggarwal, B.B., Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 270 (1995), 24995–25000.
30. 30 Goel, A., Aggarwal, B.B., Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62 (2010), 919–930.
31. 31 Mach, C.M., Chen, J.H., Mosley, S.A., Kurzrock, R., Smith, J.A., Evaluation of liposomal curcumin cytochrome p450 metabolism. Anticancer Res 30 (2010), 811–814.